By Colin Kellaher

Zymeworks unveiled a C-suite realignment that includes the departure of the biotechnology company's top finance and science officers.

Zymeworks on Monday said the moves are aimed at aligning key leadership roles with the corporate strategy the company announced in November.

Zymeworks said Leone Patterson, who joined the company as executive vice president and chief financial and business officer in September 2024, will leave the company during the first quarter.

Zymeworks said its chairman and chief executive, Kenneth Galbraith, has stepped in as interim finance chief while the company conducts a search for a successor.

Mark Hollywood, who joined Zymeworks in 2019 and had been executive vice president and head of technical and manufacturing operations, will now serve as executive vice president and chief operating officer, with expanded responsibilities, the company said.

Zymeworks said Jeff Smith, who has been chief medical officer since January 2024, will retire at the end of the month.

Sabeen Mekan, currently senior vice president of clinical development, will succeed Smith as chief medical officer, the company said.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

January 12, 2026 06:34 ET (11:34 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.